Excellent
Fully Aligned
Patient Risk:
Low
Summary
The provided claim content is fully supported by the supplied FDA label excerpts, including contraindication, anaphylaxis severity and timing, overlap with immediate post-injection reactions, and required patient actions (emergency care and discontinuation).
Category Scores
Accurate Statements
Glatiramer acetate injection is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol; reactions have included anaphylaxis.
Section 4 Contraindications: “Glatiramer acetate injection is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. Reactions have included anaphylaxis…”.
Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection.
Section 5.1 Anaphylactic Reactions: “Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection.”
Anaphylaxis can occur at any time after initiation, from as early as after the first dose up to years after initiation.
Section 5.1: “Anaphylaxis can occur at any time following initiation… from as early as after the first dose, up to years after initiation…”
If an anaphylactic reaction occurs, treatment must be immediately discontinued; unless a clear alternative etiology is identified, glatiramer acetate injection must be permanently discontinued.
Section 5.1: “If an anaphylactic reaction occurs, treatment… must be immediately discontinued… Unless a clear alternative etiology is identified, glatiramer acetate injection must be permanently discontinued [see Contraindications (4)].”
Signs/symptoms of anaphylaxis may overlap with immediate post-injection reactions; prompt identification is important to avoid delay in treatment.
Section 5.2 Immediate Post-Injection Reaction: “The symptoms… may overlap…; prompt identification of anaphylaxis is important to avoid a delay in treatment.”
Patients and caregivers should be informed of the signs and symptoms and instructed to seek immediate emergency medical care if symptoms of anaphylaxis occur.
Section 5.1 and Section 17: Section 5.1 “must seek immediate emergency medical care” and Section 17 “seek immediate emergency medical care… if they experience any signs or symptoms of anaphylactic reaction.”
Patients should be advised to contact their healthcare provider and that treatment should be discontinued immediately and permanently if anaphylactic reactions occur.
Section 17 Patient Counseling Information: “Patients should be advised… that treatment should be discontinued immediately and permanently if anaphylactic reactions occur.”
Unsupported Statements
Contradictions
Important Omissions
No omitted label elements are identified because the evaluated content is limited to contraindication/anaphylaxis safety counseling present in the supplied excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
All stated anaphylaxis risk details and required actions (emergency care and discontinuation, including permanence unless alternative cause) match the supplied FDA label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement